

C-Path's Romero, Swingle Named to 100 Most Innovative and Influential Healthcare Leaders in AZ Big Media



C-Path CEO Klaus Romero and President & COO Kristen Swingle were recently named to the 100 Most Innovative and Influential Healthcare Leaders in *AZ Big Media's* "Who's Who in Healthcare for 2025."

This recognition highlights their transformative contributions to healthcare innovation and patient-centric advancements. Dr. Romero's leadership has positioned C-Path as a global authority in regulatory-grade drug development tools, paving the way for groundbreaking approaches in precision medicine and regulatory science. His dedication to fostering collaboration and leveraging cutting-edge technologies continues to accelerate solutions for critical health challenges worldwide.

Swingle's operational leadership and deep expertise in medical and molecular sciences have been instrumental in advancing C-Path's mission. Her focus on effective communication and consensus-building thought leadership ensures that those with lived experiences remain at the heart of

every C-Path initiative.

Klaus and Kristen's tireless commitment to transforming drug development and improving lives make this a truly well-deserved honor. The edition is available now on newsstands and online; you can find their profiles and interviews on page 40 of the digital issue [here](#).



KRISTEN SWINGLE
President and chief operating officer
Critical Path Institute (C-Path)

Background: Swingle is responsible for daily operations and the development and implementation of C-Path's global strategy and goals. She has more than 20 years of experience in the medical and molecular sciences industry with a strong background in product development and manufacturing, quality and regulatory affairs management, project and fiscal management and team leadership. Swingle served as chairwoman of the Arizona Biotechnology Association board of directors from 2018 – 2023.

Source of pride: "During my tenure at Cord Blood Registry in Tucson, my team was responsible for the processing and storage of over 500,000 cord blood stem cell units and the release of over 300 stem cell units for transplant of regenerative medicine applications."

Leadership takeaway: "Every problem or challenge is solvable when caring people actively listen to others and are curious. I have tremendous appreciation for people who can solve problems, but it takes active listening to truly understand what the issue to be addressed is – ask all the questions."

Learn more: c-path.org



DR. KLAUS ROMERO
CEO
Critical Path Institute (C-Path)

Background: A distinguished clinician, scientist, scholar and executive, Dr. Romero has helped to pioneer the development of regulatory grade drug development tools that have transformed treatment approaches for Alzheimer's disease, Friedreich's ataxia, Duchenne muscular dystrophy, tuberculosis, Type 1 diabetes and polycystic kidney disease.

Leadership strength: "My most relevant trait as a leader is my unwavering commitment to fostering collaboration and inclusivity within teams. I appreciate that the strength of any organization lies in the diverse perspectives of its people, and I actively encourage open dialogue, focused on the sharing of ideas. I value a leadership approach that ensures that everyone feels valued and heard, creating an environment where innovation thrives. I can be effective at inspiring trust and empowering others, which not only enhances team cohesion but also drives collective success."

Source of pride: "My involvement in making model-informed drug development a glue between data, quantification, biomarkers, endpoints, and regulatory science. This led to C-Path becoming a world leader in regulatory grade drug development tools, continuously enabling the transition of drug development into precision medicine."

Learn more: c-path.org



ADVANCING DRUG DEVELOPMENT. IMPROVING LIVES. TOGETHER.

Like many of your industry peers, you've probably felt the weight of the drug development process – a path in need of optimization. Here's where C-Path makes a difference: Celebrating **20 years of impact** and collaborations, we are a trusted and neutral partner leading collaborations and providing our expertise to generate tools and solutions that de-risk the drug development process. Through public-private partnerships, we have accelerated drug development, and helped many companies advance better treatments for people worldwide.


Partnering with C-Path isn't just a benefit. It's an advantage.

Learn more about how C-Path can help your organization accelerate drug development, partnerships@c-path.org.

Klaus Romero, MD, MS, FCP
Chief Executive Officer



Congratulations Klaus and Kristen on being named to Arizona's Most Innovative Healthcare Leaders.



400+ Strategic Partnerships, including:

- Alzheimer's Association
- FDA & EMA
- Pfizer
- Roche
- The Michael J. Fox Foundation
- University of Arizona

Multi-decade connections with regulatory authorities

Strict neutrality standards and values

Cutting-edge guidance in predictive analytics, pharmacometrics, data sequencing and methodologies

Leading collaborative innovation

- Cell and gene-based therapies
- Digital health technologies and diverse decentralized trials
- Real-world data/evidence
- AI for optimal decision-making
- Innovative translational methods



Kristen Swingle, MS
President and Chief Operations Officer



c-path.org